$120.97−0.60%Close 13 Nov 2026 · Market value $24.66B
About Incyte
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
From Wikipedia, shared under CC BY-SA.
Company facts
| Ticker | INCY · Nasdaq |
|---|
| Sector | Biotechnology |
|---|
| Industry | Biotechnology |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 879169 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Steven H. Stein | CMO & Head of Late-Stage Dev. | 313K · < 1% | Option exercise, 6 Nov 2026 |
|---|
| Paul J. Clancy | Director | 142K · < 1% | Grant or award, 30 Sep 2026 |
|---|
| Jacqualyn A. Fouse | Director | 141K · < 1% | Grant or award, 8 Jun 2026 |
|---|
| Edmund P. Harrigan | Director | 86.2K · < 1% | Grant or award, 30 Sep 2026 |
|---|
| Pablo J. Cagnoni | President, Global Head of R&D | 84.6K · < 1% | Option exercise, 15 Oct 2026 |
|---|
| Katherine A. High | Director | 75.3K · < 1% | Grant or award, 8 Jun 2026 |
|---|
| Thomas Tray | Principal Accounting Officer | 70.9K · < 1% | Sale under a 10b5-1 plan, 3 Nov 2026 |
|---|
| Otis W. Brawley | Director | 59.3K · < 1% | Grant or award, 8 Jun 2026 |
|---|
| Christiana Stamoulis | EVP & Chief Financial Officer | 57.5K · < 1% | Shares withheld for tax, 15 Jul 2025 |
|---|
| Susanne Schaffert | Director | 47.2K · < 1% | Grant or award, 10 Jun 2025 |
|---|
| Heeson Lee | EVP, Head of Incyte Intl | — | Shares withheld for tax, 1 Oct 2026 |
|---|
| BAKER BROS. ADVISORS LP | Director · 10% owner | — | Grant or award, 30 Sep 2026 |
|---|
| Gardner David H | EVP, Chief Strategy Officer | — | Shares withheld for tax, 22 Sep 2026 |
|---|
| Basi Ramitpal K | EVP, Human Resources | — | Shares withheld for tax, 25 Aug 2026 |
|---|
| Mayes Patrick A | EVP & Chief Scientific Officer | — | Sale under a 10b5-1 plan, 5 Aug 2026 |
|---|
| William J. Meury | Chief Executive Officer · Director | — | Grant or award, 16 Jul 2026 |
|---|
| Mohamed Issa | EVP, Head of U.S. Commercial | — | Grant or award, 16 Jul 2026 |
|---|
| Hoffman Richard A. | EVP & General Counsel | — | Grant or award, 16 Jul 2026 |
|---|
| BAKER FELIX | Director · 10% owner | — | Grant or award, 30 Jun 2026 |
|---|
| BIENAIME JEAN JACQUES | Director | — | Grant or award, 8 Jun 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
INCY in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.